MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, RARE had $252M increase in cash & cash equivalents over the period. -$472M in free cash flow.

Cash Flow Overview

Change in Cash
$252M
Free Cash flow
-$472M

Unit: Million (M) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Net loss
-575
Stock-based compensation
153
Amortization of discount on marketable securities, net
4
Depreciation and amortization
35
Non-cash royalty revenue
112
Non-cash interest expense on liabilities for sales of future royalties
62
Other
2
Accounts receivable
31
Inventory
6
Prepaid expenses and other assets
10
Accounts payable, accrued, and other liabilities
24
Net cash used in operating activities
-466
Purchase of property, plant, and equipment
6
Purchase of marketable securities
186
Proceeds from sale of marketable securities
0
Proceeds from maturities of marketable securities
444
Payments for intangible asset
15
Other
1
Net cash provided by (used in) investing activities
236
Proceeds from the sale of future royalties, net
392
Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net
0
Proceeds from the issuance of common stock in connection with at-the-market offering, net
80
Proceeds from the issuance of common stock under equity plans, net
6
Proceeds from issuance of equity from noncontrolling interest
0
Other
0
Net cash provided by financing activities
478
Effect of exchange rate changes on cash
4
Net increase (decrease) in cash, cash equivalents, and restricted cash
252
Cash and cash equivalents at beginning of period
184
Cash and cash equivalents at end of period
436
Unit: Million (M) dollars

Time Plot

Show the time plot by selecting a row from the table.

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE)